← feed

Is NCT02365662 results overdue?

Yes — results are overdue. Primary completion was 2018-03-15; the FDAAA-801 reporting deadline (2019-03-15) passed 2701 days ago and no results are posted on ClinicalTrials.gov.

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

NCT IDNCT02365662 ↗
SponsorAbbVie (INDUSTRY)
Public issuerAbbVie Inc. — ABBV (CIK 0001551152) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusTERMINATED
Primary completion2018-03-15 (ACTUAL)
Reporting deadline2019-03-15 (completion + 365d)
Days overdue2701
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 1110190f3df0f68b… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02365662. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →